Literature DB >> 29322707

Knowledge, Attitudes, Beliefs and Practices of Physicians Regarding Idiopathic Pulmonary Fibrosis and the Impact of a Continuing Medical Education Program.

Sahajal Dhooria1, Inderpaul Singh Sehgal1, Ritesh Agarwal2, Ashutosh Nath Aggarwal2, Digambar Behera3.   

Abstract

BACKGROUND: Significant deficiencies have been identified previously in the knowledge of physicians regarding the current diagnosis and management of idiopathic pulmonary fibrosis (IPF). Whether a continuing medical education (CME) program helps in overcoming these deficiencies has never been studied.
METHODS: This was a questionnaire-based study performed to assess the knowledge, attitudes, beliefs and practices of physicians regarding IPF before and after attending a CME program at a tertiary care teaching Institute in northern India. A questionnaire comprising of 18 questions on knowledge, attitudes, beliefs and practices regarding IPF (designed by Delphi method) was self-administered by the participants prior to (pretest) and after (posttest) attending the program. The pretest and posttest knowledge and belief scores (maximum achievable score 17) were compared.
RESULTS: Of the total 98 physicians who agreed to participate, 84 completed the pretest questionnaire. The mean (SD) total score for knowledge and beliefs questionnaire was 10.7 (3.5). The mean (SD) pretest and posttest scores of 52 subjects, who completed both the questionnaires were 10.3 (3.4) and 11.1 (2.9) respectively with a mean increase of 0.8 (p=0.048). The proportion of participants who scored >50% increased (p=0.046) from 41 (78.8%) to 48 (92.3%) between the pretest and posttest questionnaires. Only 54.8% and 47.6% of the participants responded correctly to the questions on CT features and drugs useful for IPF, respectively.
CONCLUSIONS: Significant deficiencies were noted in the knowledge of IPF among a small group of physicians attending a CME. A CME program with didactic lectures helps improving the knowledge only marginally.

Entities:  

Mesh:

Year:  2017        PMID: 29322707

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  7 in total

1.  A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis.

Authors:  Sahajal Dhooria; Ritesh Agarwal; Inderpaul Singh Sehgal; Kuruswamy Thurai Prasad; Valliappan Muth; Mandeep Garg; Amanjit Bal; Ashutosh Nath Aggarwal; Digambar Behera
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-06-30       Impact factor: 0.670

2.  Spectrum of interstitial lung diseases at a tertiary center in a developing country: A study of 803 subjects.

Authors:  Sahajal Dhooria; Ritesh Agarwal; Inderpaul Singh Sehgal; Kuruswamy Thurai Prasad; Mandeep Garg; Amanjit Bal; Ashutosh Nath Aggarwal; Digambar Behera
Journal:  PLoS One       Date:  2018-02-08       Impact factor: 3.240

3.  Idiopathic pulmonary fibrosis: Educational needs of health-care providers, patients, and caregivers.

Authors:  Deepa Ramadurai; Stephanie Corder; Tara Churney; Bridget Graney; Andrea Harshman; Sarah Meadows; Jeffrey J Swigris
Journal:  Chron Respir Dis       Date:  2019 Jan-Dec       Impact factor: 2.444

4.  Fellowship Education in Interstitial Lung Disease. A National Survey of Program Directors and Trainees.

Authors:  Jake G Natalini; Stacey M Kassutto; Tristan J Huie; Maryl E Kreider
Journal:  ATS Sch       Date:  2020-08-13

5.  Real world efficacy and safety of nintedanib in idiopathic pulmonary fibrosis: A single center, observational study from India.

Authors:  Deepak Talwar; Deepak Kumar Prajapat; Dhruv Talwar
Journal:  Lung India       Date:  2022 Jan-Feb

6.  A multicenter survey study of antifibrotic use for symptomatic patients with post-COVID-19 interstitial lung abnormalities.

Authors:  Sahajal Dhooria; Venkata Nagarjuna Maturu; Deepak Talwar; Sachin Kumar; Ajay Handa; Priya Nath Agrawal; Aditya Jindal; P S Tampi; Abhishek Goyal; Dipesh Maskey; Ashutosh Nath Aggarwal; Digambar Behera; Surinder Kumar Jindal
Journal:  Lung India       Date:  2022 May-Jun

7.  Incidence, prevalence, and national burden of interstitial lung diseases in India: Estimates from two studies of 3089 subjects.

Authors:  Sahajal Dhooria; Inderpaul Singh Sehgal; Ritesh Agarwal; Valliappan Muthu; Kuruswamy Thurai Prasad; Soundappan Kathirvel; Mandeep Garg; Amanjit Bal; Ashutosh Nath Aggarwal; Digambar Behera
Journal:  PLoS One       Date:  2022-07-21       Impact factor: 3.752

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.